Lysosomal Storage Disorders

Cover
John A. Barranger, Mario Cabrera-Salazar
Springer Science & Business Media, 16.10.2007 - 564 Seiten
Scientific progress has been rapid in lysosomal biology during the last six decades. Its application to human disease is nothing less than spectacular. In no other group of disorders has knowledge and clinical utility progressed so speedily. Recall that the organelle was described in just 1955. Since then, the biochemical alterations and storage materials were described, the enzyme deficiencies discovered, the gene coding of these glycoproteins cloned and thousands of mutations defined. These advances have resulted in highly improved diagnosis for more than 50 diseases. For five diseases, including the most common lysosomal storage disorder, molecular therapy is a reality, extremely effective and very safe. This higher plateau of medical approaches to human disease is something to which all translational scientists aspire and only a few actually witness. The relief of pain and suffering is a tribute to the ideas and work of many dedicated investigators. Much of that work is presented in this text. Despite our ability to treat some of these diseases through enzyme replacement therapy (ERT) and, accurately define different diseases that look alike, there is much to be learned about lysosomal disease. With each step up the barrier to knowledge, a new point of view is attained, a fresh perspective. Much is seen more clearly and many “allegories of the cave” are dispelled forever. Yet, our new view demands a new vision drawing us to find better definitions of what we see. This is how it has been with lysosomal diseases.
 

Was andere dazu sagen - Rezension schreiben

Es wurden keine Rezensionen gefunden.

Inhalt

LYSOSOMAL BIOGENESIS AND DISEASE
6
THE CONCEPT OF TREATMENT IN LYSOSOMAL STORAGE DISEASES
37
COMPLEX LIPID CATABOLISM
45
RETROVIRAL VECTORS FOR GENE THERAPY
53
ADENOVIRUS IN GENE THERAPY
68
SETTING BACK THE CLOCK ADENOVIRALMEDIATED GENE THERAPY FOR LYSOSOMAL STORAGE DISORDERS
81
ADENOASSOCIATED VIRALMEDIATED GENE THERAPY OF LYSOSOMAL STORAGE DISORDERS
97
HERPES SIMPLEX VIRUS VECTORS FOR GENE THERAPY OF LYSOSOMAL STORAGE DISORDERS
110
METACHROMATIC LEUKODYSTROPHY
284
FABRY DISEASE
307
GAUCHER DISEASE REVIEW AND PERSPECTIVES ON TREATMENT
319
THERAPEUTIC GOALS IN THE TREATMENT OF GAUCHER DISEASE
345
THE NEURONAL CEROID LIPOFUSCINOSES CLINICAL FEATURES AND MOLECULAR BASIS OF DISEASE
371
MUCOPOLYSACCHARIDOSIS I
389
MUCOPOLYSACCHARIDOSIS II
406
SANFILIPPO SYNDROME CLINICAL GENETIC DIAGNOSIS AND THERAPIES
415

GENE THERAPY OF LYSOSOMAL STORAGE DISORDERS BY LENTIVIRAL VECTORS
133
SUBSTRATE REDUCTION THERAPY
152
NEWBORN SCREENING FOR LYSOSOMAL STORAGE DISORDERS
169
GENETIC COUNSELING FOR LYSOSOMAL STORAGE DISEASES
179
NEURAL STEM CELL THERAPY IN LYSOSOMAL STORAGE DISORDERS
197
THE GM1 GANGLIOSIDOSES
217
THE GM2 GANGLIOSIDOSES
229
ACID SPHINGOMYELINASEDEFICIENT NIEMANNPICK DISEASE
257
KRABBE DISEASE GLOBOID CELL LEUKODYSTROPHY
269
MUCOPOLYSACCHARIDOSIS IV Morquio Syndrome MPS IV
433
MUCOPOLYSACCHARIDOSIS TYPE VI MPS VI MaroteauxLamy Syndrome
447
MUCOPOLYSACCHARIDOSIS TYPE VII SLY DISEASE CLINICAL GENETIC DIAGNOSIS AND THERAPIES
457
POMPE DISEASEGLYCOGENOSIS TYPE II ACID MALTASE DEFICIENCY
473
LYSOSOMAL FREE SIALIC ACID STORAGE DISORDERS SALLA DISEASE AND ISSD
499
CYSTINOSIS
512
ICELL DISEASE
529
Index
538
Urheberrecht

Andere Ausgaben - Alle anzeigen

Häufige Begriffe und Wortgruppen

Über den Autor (2007)

John A. Barranger, M.D., Ph.D., is a tenured professor in the departments of human genetics, molecular genetics and biochemistry, and pediatrics at the University of Pittsburgh.

He is also director of the Human Gene Therapy Applications Laboratory, the Center for the Study and Treatment of Jewish Genetic Diseases, and the Comprehensive Gaucher Disease Treatment Center. Additionally, he is co-director of the Human Gene Therapy Center.

Previously, Dr. Barranger was a clinical associate at the National Institutes of Health (NIH), where, from 1976 to 1978, he served in the clinical investigations and therapeutics section, Developmental and Metabolic Neurology Branch (DMNB), National Institute of Neurological and Communicative Disorders and Stroke. He ultimately became chief of the molecular and medical genetics section of the DMNB and associate branch chief. Dr. Barranger received a doctorate and medical degree from the University of Southern California Los Angeles, and completed an internship and residency in pediatrics at the University of Minnesota.

Dr. Barranger has devoted his professional career to the study of inherited metabolic diseases, particularly lysosomal storage disorders. His research interests include biochemical and molecular genetics, enzyme therapy, gene transfer, and models of genetic disease. As a result of his investigation of the structure of glucocerebrosidase and receptors on macrophages, Dr. Barranger developed successful enzyme replacement therapy for Gaucher disease, an inherited, potentially lethal lysosomal disorder that affects more than 10,000 people in the United States.

This therapy received Food and Drug Administration approval in 1991 and serves as a treatment model for more than 50 related lysosomal storage disorders.

Currently, Dr. Barranger is focused on developing models of inherited diseases to study their pathobiology and treatment by enzyme and gene therapy.
Included among Dr Barranger's honors are the March of Dimes Health Career Award, United States Public Health Service Commendation Medal, Arthur S. Flemming Award and the Scientific Achievement Award of the National Gaucher Foundation.

In addition to consulting for government and industry, Dr Barranger is a member of numerous professional organizations, including the American Society of Biochemistry and Molecular Biology, American Society of Human Genetics, Society for Inherited Metabolic Disorders, and the Society for Pediatric Research.

Mario A. Cabrera-Salazar, MD is a Staff Scientist at Genzyme Corporation in Framingham. MA. He is involved in the development of enzymatic and gene therapies for lysosomal storage disorders and for neurodegenerative diseases in the department of Genetic Disease Science.

Bibliografische Informationen